Skip to content
value.today

Senomyx

SNMXUnlisted company
No market cap data
Compare
World rank
—
no current market cap
Revenue
$29 M
For year ending December-2017
Net income
—
Employees
—

Senomyx in brief

Senomyx is an unlisted company in the Diagnostics and Research industry, based in San Diego, USA. It was founded in 1999. In the year to December 2017 it had sales of $29 M.

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Senomyx

Senomyx is an American biotechnology company that develops food additives. The company claims to have "reverse engineered" human taste and aroma receptors. It was founded by Lubert Stryer and Paul Nevsky in 1998. On September 17, 2018, private Swiss company Firmenich completed the acquisition of Senomyx.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Senomyx timeline

2 events, 1999–2001
  1. 1999
  2. 🏁
    · approximate
    Founded by Lubert Stryer
  3. 2001
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.

Events of Senomyx from Wikidata and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

More about Senomyx

Acquisitions and changes
Taken over: the company reported a change in control and the delisting of its shares to the SEC on 2 November 2018 (Form 8-K).

Market cap history

Not enough history yet.

Key ratios

market cap and latest results
P/E ratio
—
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
—
Operating margin
-4.5%
Return on equity
—
Liabilities / assets
32.0%
Revenue growth
+27.3%
R&D / revenue
51.2%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2010: revenue $29M, net income —$29MFY10Fiscal year ending Dec 2011: revenue $32M, net income —$32MFY11Fiscal year ending Dec 2012: revenue $31M, net income —$31MFY12Fiscal year ending Dec 2013: revenue $29M, net income —$29MFY13Fiscal year ending Dec 2014: revenue $28M, net income —$28MFY14Fiscal year ending Dec 2015: revenue $25M, net income —$25MFY15Fiscal year ending Dec 2016: revenue $23M, net income —$23MFY16Fiscal year ending Dec 2017: revenue $29M, net income —$29MFY17
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2017$29M+27.3%$-1M——
Dec 2016$23M-7.4%$-11M——
Dec 2015$25M-10.1%$-13M——
Dec 2014$28M-5.6%$-12M——
Dec 2013$29M-6.5%$-12M——
Dec 2012$31M-0.8%$-9M——
Dec 2011$32M+9.3%$-9M——
Dec 2010$29M—$-11M——

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2017$2M$1M$1M$-0.03—
Dec 2016$-12M$0M$-12M$-0.24—
Dec 2015$-8M$1M$-9M$-0.29—
Dec 2014$-14M$0M$-14M$-0.29—
Dec 2013$-10M$1M$-10M$-0.29—
Dec 2012$-12M$1M$-14M$-0.23—
Dec 2011$-14M$3M$-17M$-0.22—
Dec 2010$22M$1M$21M$-0.28—

SEC filings

Official filings of Senomyx with the US Securities and Exchange Commission.

Annual results

Revenue
$29 M
Operating income
$-1 M
Net income
—

For year ending December-2017 · source: SEC filing

Balance sheet

Total assets
$28 M
Total liabilities
$9 M
Total equity
$19 M

As of December-2017

Insider trading at Senomyx#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
16
since
Senomyx: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Stephen A. BlockDirectorTender in a change of control-1,000$1.500$2 K0Form 4
filed Kent SnyderDirectorTender in a change of controlindirect-414,288$1.500$621 K0Form 4
filed Mary Ann GrayDirectorTender in a change of control-10,000$1.500$15 K0Form 4
filed Catherine Chai-zon LeeSr. V.P. Gen. Counsel & Sec.Tender in a change of control-36,920$1.500$55 K0Form 4
filed John PoyhonenPresident & CEO, DirectorTender in a change of control-111,469$1.500$167 K0Form 4
filed E. Thomas Erdmann IIIDirectorTender in a change of control-500$1.500$7500Form 4
filed David Carl HumphreyV.P. & Chief Financial OfficerTender in a change of control-432,810$1.500$649 K0Form 4
filed Sharon WickerSr VP & Chf Comm Dvlpt OfficerTender in a change of control-131,897$1.500$198 K0Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Senomyx scorecard#

Passes 3 of the 9 checks that could be worked out. Fiscal year 2017.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth1 of 5
    • ✓Revenue grew in the newest year27.3%Revenue up 27.3% in fiscal 2017.
    • ✗Revenue up more than 5% a year over three years2.0%2.0% a year over the three years to fiscal 2017.
    • ✗Faster growth over three years than its peers' median2.0%2.0% a year against Diagnostics and Research's median of 3.6% (64 companies).
    • ✗Earnings per share grew in the newest year-0.03 vs -0.24Diluted EPS -0.03 in fiscal 2017 against -0.24 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2017.
  • Profitability1 of 2
    • –Profitable in the newest yearNo net income on file.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • ✗Operating margin above its peers' median-4.5%-4.5% against Diagnostics and Research's median of -2.4% (66 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-4.5%-4.5% in fiscal 2017 against -44.1% in 2014.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities4.6×Current ratio 4.58 at the end of fiscal 2017.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2017.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Senomyx: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Senomyx: statements by fiscal year
PeriodTrendFY 2017to Dec 31, 2017FY 2016to Dec 31, 2016FY 2015to Dec 31, 2015FY 2014to Dec 31, 2014FY 2013to Dec 31, 2013FY 2012to Dec 31, 2012FY 2011to Dec 31, 2011FY 2010to Dec 31, 2010FY 2009to Dec 31, 2009
Income statement
Revenue29232528293132r29r16
Research and development151922252727r27r2728
Selling, general and administrative12121313121212——
General and administrative—————12121314
Operating expenses31343840414140r40r42
Operating income−1.3−11−13−12−12−9.3−8.9−11−26
Other non-operating income (expense)0.10.10.00.00.00.10.10.30.2
Earnings per share, basic-0.03-0.24-0.29-0.29-0.29-0.23-0.22-0.28-0.85
Earnings per share, diluted-0.03-0.24-0.29-0.29-0.29-0.23-0.22-0.28-0.85
Shares, weighted average (basic)——————403831
Shares, weighted average (diluted)474544434140403831
Balance sheet
Cash and cash equivalents6.23.64.84.01115162125
Short-term investments9.6————————
Receivables7.15.43.22.32.12.72.41.5—
Inventory1.62.32.42.30.2————
Other current assets0.51.00.71.00.7r0.80.71.8r—
Current assets2521293233405659—
Property, plant and equipment2.62.73.33.85.77.99.49.7—
Total assets2824333842536885—
Accounts payable0.61.1r0.4r1.1r0.7r0.4r0.3r7.3—
Current liabilities5.55.79.61218182026—
Retained earnings−280−278−267−255−243−231−222−213—
Shareholders' equity191520242026303218
Total equity———————32—
Total liabilities and equity2824333842536885—
Shares outstanding4845454341404039—
Cash-flow statement
Share-based compensation3.24.45.36.24.04.54.84.9—
Cash from operating activities2.0−12−8.2−14−9.7−12−1422−9.4
Capital expenditure−0.6−0.1−0.7−0.3−0.6−1.5−3.1−1.0−0.4
Cash from investing activities−1.49.15.7−3.63.8117.6−46−0.2
Shares issued2.11.23.410.01.70.71.4200.7
Cash from financing activities2.11.23.410.01.70.71.4200.7
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2018. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Senomyx#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Delisting notice 1 · Restructuring 1 · Taken over and delisted 1 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 6 · Material agreement 5 · Agreement ended 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 3 · Results announced 8

Senomyx: events reported to the SEC
FiledWhat happenedFiling
Taken over and delistedChange in controlAcquisition or sale completedDirectors and officersShareholder rights changedBylaws or fiscal year changed8-K
Material agreement8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Agreement ended8-K
Material agreement8-K
Results announced8-K
Bylaws or fiscal year changed8-K
Results announced8-K
Delisting notice8-K
Directors and officers8-K
Material agreementShareholder vote8-K/A
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Material agreement8-K
Restructuring8-K
Results announced8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 2, 2018

Layoffs at Senomyx#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2015–2016
Latest
—
2016-12-02
Senomyx: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2016············—
2015············—
Senomyx: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

How Senomyx compares in Diagnostics and Research

  • Revenue$29 M · higher than 22% of 123
  • Revenue growth27.3% · higher than 84% of 89

Peer comparison · Diagnostics and Research

CompanyMarket capP/ENet marginRev. growth
Senomyx🇺🇸———+27.3%
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%
Danaher Corporation🇺🇸$166.7 B38.5×16.9%+2.9%
WuXi AppTec Co., Ltd.🇨🇳$70.4 B25.4×42.1%—
Natera, Inc.🇺🇸$58.7 B—-5.7%+35.9%
Siemens Healthineers AG🇩🇪$52.8 B22.9×8.7%—
Lonza Group AG🇨🇭$51.9 B—-4.2%—
Agilent Technologies, Inc.🇺🇸$48.8 B33.9×19.5%+6.7%
IQVIA Holdings Inc.🇺🇸$45.1 B32.4×8.1%+5.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Annual results:
For year ending December-2017
Balance sheet:
As of December-2017
Profile updated:
Nov 16, 2026

Figures from SEC filing, Wikidata, Wikipedia, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Senomyx? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Senomyx's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Senomyx? Suggest a correction